pharmaphorum

MAY 11, 2022

US digital health firm Osmind – which had developed an electronic health record (EHR) system for patients with mental illness – has added to its finances with a $40 million Series B financing. The San Francisco-based company says it will use the proceeds of the financing to expand its workforce and make improvements to its EHR platform, which is directed towards novel interventions for mental health such as psychedelic medicines and neuromodulation therapies like transcranial magnetic stimulatio

59

59

Pharma Times

MAY 11, 2022

Nirsevimab is the first investigational immunisation designed to protect all infants across the RSV season with a single dose

52

52

pharmaphorum

MAY 11, 2022

Roche’s anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuster Tecentriq. When tiragolumab missed the mark in the SKYSCRAPER-02 trial in extensive stage small-cell lung cancer (ES-SCLC) in January, Roche said it was a challenging indication, and it was hoping for better results in the SKYSCRAPER-01 study in non-small cell lung cancer (NSCLC).

Immunization 59

Immunization 59

Compounding Pharmacy of America

MAY 11, 2022

Maintaining excellent health is one of the most crucial components of fertility for every woman. That means that one of the best ways to boost your fertility may be by ensuring your hormones, vitamins, and nutrients are at optimal levels. The post The Top Vitamins and Supplements for Fertility appeared first on The Compounding Pharmacy of America.

Compounding Pharmacies 52

Compounding Pharmacies Compounding 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

NF2 BioSolutions

MAY 11, 2022

I’m Grace and I am one of the two NF2 BioSolutions UK PhD students at the University of Manchester. I am currently looking at the body’s immune cells that can invade into NF2 brain tumours which may provide new ideas that could lead to the development of targeted drugs for those with NF2. This is the goal of my 3-year PhD, but I thought I would break that down into my day-to-day routine in this ‘Day in the Life’ blog post.

Immunization 52

Immunization 52

Roots Analysis

MAY 11, 2022

Over the years, the drug hunters have tried to target the tens of thousands of proteins responsible for sickness and health. But a vast majority of them have remained out of reach. While, the scientific evolution has led to the development of potent and selective small-molecule inhibitors of protein function, but still, multiple targets of high biomedical relevance are highly challenging targets for typical small-molecule drugs.

52

52

pharmaphorum

MAY 11, 2022

TALLINN, Estonia, May 11, 2022 – Viseven is proud to announce its latest venture – a brand new Center of Excellence in Jaipur, India. As a Global Marketing Technology Services Provider for Life Sciences and Pharma industries with over a decade of experience, Viseven continues to deliver exceptional services for its clients around the world. The Center of Excellence in India is yet another affiliate on the long list of Viseven teams worldwide.

Communication 52

Communication 52

Pharma Times

MAY 11, 2022

The project will analyse risks from Sano Genetics’ data from 3,000 UK adults suffering from long COVID

49

49

Med Ed 101

MAY 11, 2022

I don’t take a break from clinical content very often, but when I do, it’s usually something that is very important to me personally. Every day, I try to think about what might help a fellow healthcare professional use medications more wisely. I’ve been blogging since 2013 and podcasting (Real Life Pharmacology) since 2018. Hitting […].

40

40

Pharma Mirror

MAY 11, 2022

Abzena, the leading Partner Research Organization (PRO) providing integrated discovery, development and manufacturing of biologics and antibody drug conjugates (ADCs) has announced the appointment of Dr. Petra Dieterich, DPhil, MBA, as scientific lead. Reporting to Abzena’s chief technology officer Dr. Louise Duffy, Dr. Dieterich will use her extensive technical knowledge and leadership experience to support Abzena’s successful drug development and manufacturing operations, ultimately assisting

40

40

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 11, 2022

Danish drugmaker Novo Nordisk has traditionally generated its pipeline mainly from internal R&D, but a new alliance with venture capital firm Flagship Pioneering signals another departure from that strategy. The partnership with Flagship will bring Novo Nordisk into closer contact with the VC’s portfolio of 41 biotech companies, with the aim of creating a portfolio of “transformational” medicines for cardiometabolic and rare diseases.

Vaccines 126

Vaccines 126

pharmaphorum

MAY 11, 2022

Antimicrobial resistance is a growing problem and one that is already claiming over a million lives per year. The situation is urgent but finding a sustainable solution is a difficult prospect, finds Ben Hargreaves. Alexander Fleming discovered the world’s first antibiotic, penicillin, in 1928. However, the difficulty in developing a method to adequately produce sufficient levels of the product meant that the age of the antibiotic did not truly begin until the 1940s.

Mayo Clinic 145

Mayo Clinic Vaccines 145

pharmaphorum

MAY 11, 2022

A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respiratory tract infections caused by the pathogen. The data – presented this week at the European Society for Paediatric Infectious Diseases meeting – come as nirsevimab is being reviewed by the EMA after it was filed for approval in February to prevent RSV infections in newborn infants.

Vaccines 64

Vaccines FDA 64